INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Corporate insider
KD

Karydas Daphne

DirectorCIK 0001816952

EDGAR filingsOpen in network
Disclosed transactions8
Buys / sells0 / 3
Max Insider Score54
Connections2with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$36K
3,000 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    COMPASS Pathways plcDirector · May 29, 2026
  • Insider ofevidence
    Mineralys Therapeutics, Inc.Director · Nov 13, 2025
0
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
—
3,000 sh
Jun 17, 2026
Jun 17, 2026
traded Jun 17, 2026
+0d
SEC FORM 4

Evidence

27
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
3,000 sh
Jun 17, 2026Jun 17, 2026
traded Jun 17, 2026
+0dSEC FORM 4

Evidence

9
KD
Karydas DaphneDirector
CMPSCOMPASS Pathways plc
Grant or award
A—
21.1K sh
May 27, 2026May 29, 2026
traded May 27, 2026
+2dSEC FORM 4

Evidence

21
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Option exercise
M—
15.0K sh
Nov 13, 2025Nov 13, 2025
traded Nov 13, 2025
+0dSEC FORM 4

Evidence

51
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$226K
4,885 sh
Nov 13, 2025Nov 13, 2025
traded Nov 13, 2025
+0dSEC FORM 4

Evidence

54
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Open-market sale
SELL$463K
10.1K sh
Nov 13, 2025Nov 13, 2025
traded Nov 13, 2025
+0dSEC FORM 4

Evidence

12
KD
Karydas DaphneDirector
MLYSMineralys Therapeutics, Inc.
Option exercise
M$153K
15.0K sh
Nov 13, 2025Nov 13, 2025
traded Nov 13, 2025
+0dSEC FORM 4

Evidence